The market is registering growth due to the high demand for tissues and organs for transplantation, technological advancements and innovations, and rising compliance for drug discovery processes. 3D bioprinting is an additive manufacturing technology and refers to the process of creating 3D structures by making use of live cells. The process utilizes 3D printing technologies for creating live tissue or cell structures.
In terms of technology, the 3Dbioprinting market is categorized into pneumatic extrusion, laser-based, syringe-based, inkjet-based, and others. Among these, the syringe-based category dominated the market during the historical period (2012–2015) and is further predicted to account for the largest share of the market during the forecast period, contributing a share of over 35.0% in 2022. The pneumatic extrusion category is expected to grow at the fastest pace during the forecast period due to the advantageous features of this technology, as compared to the other technologies.
Receive a Free Sample Copy of this Report:
When application is taken into consideration, the 3Dbioprinting market is divided into pharmaceutical, tissue & organ regeneration, 3D cell culture, and others. Out of these, the tissue & organ regeneration application dominated the market during the historical period and is further predicted to account for the largest revenue share of more than 55.0% in 2022. The 3D cell culture category is expected to witness the fastest growth during the forecast period. This is because extensive research is being carried out in the field of stem cell around the world.
The increasing stem cell research is a key trend in the 3D bioprinting market. Stem cells are the undifferentiated live cells which have the capability of being differentiated into specialized tissues, cells, or organs. These cells are being utilized for the treatment of disorders that involve destruction of tissue. Stem cells can also act as differentiated cells when regulated under controlled cell culture conditions. Due to these benefits, the research activities in the field have increased significantly and the 3D bioprinting technology s being employed for placing stem cells for tissue regeneration.
Make an Enquiry before Purchase:
The rising compliance for drug discovery processes is a major driving factor of the 3D bioprinting market. Several drugs are not given approval by regulatory authorities because of their toxicity to certain organs, which cannot be predicted during the pre-clinical trial process. However, tissues developed through 3D bioprinting, including liver tissue, help in predicting drug toxicity and improving drug efficacy. 3D bioprinting also saves time during clinical trials. Because of these factors, several pharmaceutical companies are collaborating with 3D bioprinting companies for testing their drugs during the early stage of clinical trials.
Hence, the market is expanding due to the growing compliance for drug delivery processes and increasing demand for tissues and organs for transplantation.